Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer

Trial Profile

Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2013

At a glance

  • Drugs Everolimus (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Jul 2012 Planned end date changed from 1 Feb 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 14 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top